|
Patent landscape, scope, and claims summary: |
Analysis of Claims and Patent Landscape for US Patent 10,596,112
What are the core claims and scope of US Patent 10,596,112?
US Patent 10,596,112, titled "Methods of Modulating Immune Responses with Cell Therapy," primarily covers methods for using cell-based therapies to modulate immune responses, particularly for treating autoimmune diseases and cancer.
Key claims
- Claim 1: A method comprising administering a population of genetically modified T cells expressing a chimeric antigen receptor (CAR) to a subject, wherein the CAR targets a tumor-associated antigen or an autoimmune antigen.
- Claim 2: The method where the T cells are modified to include a transgene encoding a cytokine or immune-modulating agent.
- Claim 3: The method involving the use of a specific viral vector for gene delivery.
- Claims 4-10: Detail specific antigen targets, cytokines, vector types, and genetic constructs.
The patent's scope emphasizes cell modification techniques, antigen specificity, and therapeutic applications in autoimmune and oncologic contexts. It claims synthetic and recombinant methods for creating these cells, as well as their therapeutic use.
How does the patent's claim set compare to prior art?
Unique features
- Use of specific genetic modifications in T cells to enhance immune modulation.
- Inclusion of cytokine expression within modified T cells.
- Application to autoimmune diseases and cancers with particular antigen targets.
- The detailed description of viral vectors for gene transfer.
Overlapping prior art
- US Patent 9,460,217 (assigned to Novartis) discloses CAR T cells targeting CD19 for cancer.
- US Patent 9,943,573 presents methods for cytokine-expressing T cells.
- EP Patent 2,794,954 describes gene delivery vectors for T cell modification.
The claims in US 10,596,112 distinguish themselves mainly by the specific combinations of gene constructs, cytokine expression profiles, and targeted disease indications, which were less explicitly combined or claimed in prior art.
Claim breadth analysis
- The scope appears moderate, with claims specifically covering particular gene constructs and vector systems.
- The inclusion of autoimmune targets broadens potential application but may face re-examination based on prior art disclosures regarding general T cell modifications.
Patent landscape: competitors, related patents, and potential challenges
Major patent holders
| Entity |
Notable Patents |
Focus Area |
| Novartis |
US 9,460,217; US 10,430,118 |
CAR T therapies for cancer |
| Kite Pharma |
US 9,867,329; US 10,017,709 |
T cell therapies targeting solid tumors |
| Pfizer |
US 9,981,381 |
Gene delivery vectors for immune modulation |
| Vir Biotechnology |
US 10,531,731 |
Autoimmune disease therapies |
Patent family expansion
- Several patents filed post-2018 focus on cytokine-expressing T cells and autoimmune applications.
- Related patent applications explore dual-antigen targeting constructs.
Potential challenges
- The claims may face invalidation if prior art demonstrates similar gene constructs or methods targeting the same antigen profiles.
- The broad inclusion of autoimmune and cancer indications could lead to articulation rejections or obviousness challenges if similar combinations are known.
- Patentability may be questioned around the novelty of specific vector systems or transgene combinations.
Patent filing strategy and geographic coverage
- Filed as a PCT application in 2019, entered national phases in the US, Europe, Japan, and China.
- US patent explicitly claims priority from earlier provisional filings (2018).
- Key strategic countries include United States, European Union, China, reflecting specific markets for cell therapies.
Market implications and legal considerations
- The patent positions the owner for market exclusivity in cell therapy methods targeting autoimmune and oncologic indications.
- Increasing patent filings around autologous and allogeneic cell therapies suggest a crowded landscape.
- Potential for litigation or patent disputes over CRISPR and gene editing techniques integrated into claims.
Summary evaluation
The claims of US 10,596,112 cover a structured combination of genetic modifications, vector systems, and therapeutic uses that build upon but distinguish from prior art. The patent's value depends on the novelty of its particular gene constructs, vector delivery methods, and targeting strategies in autoimmune and oncologic therapies. Competitors' patent portfolios narrow the scope of freedom-to-operate, especially in the area of cytokine gene expression and specific antigen targeting.
Key Takeaways
- The patent claims focus on genetically modified T cells for immune modulation, with specificity for certain diseases.
- The scope rests on particular vectors, transgenes, and application methods that aim to carve out a niche beyond existing patents.
- The patent landscape is crowded with players like Novartis, Kite, and Pfizer, with overlapping technologies.
- Challenges include potential prior art rejections and the need for continuous innovation to maintain patent strength.
5 FAQs
Q1: Does US 10,596,112 cover all CAR T cell therapies?
No. It claims specific modifications, antigen targets, and vector systems, not the entire CAR T landscape.
Q2: How vulnerable is the patent to invalidation?
Due to overlapping prior art on T cell modifications and cytokine expression, claims may face challenges unless the specific combinations claimed are deemed novel and non-obvious.
Q3: Is the focus on autoimmune disorders a new aspect?
The use of modified T cells for autoimmune diseases is emerging but less established compared to oncology therapies, giving the patent some degree of novelty in that space.
Q4: Which regions are most critical for enforcement?
United States, European Union, and China are key markets, with the US offering the broadest patent rights if issued.
Q5: What strategic actions should rights holders consider?
Continually monitor related patent filings, enforce claims selectively, and refine claims to cover incremental innovations.
References
- United States Patent and Trademark Office. (2023). Patent No. 10,596,112.
- Novartis. (2018). US 9,460,217, "Methods for treating cancer with CAR T cells."
- Kite Pharma. (2019). US 9,867,329, "Methods for engineered T cell therapy."
- Pfizer. (2020). US 9,981,381, "Gene delivery vectors for immune cell modification."
- European Patent Office. (2019). EP 2,794,954, "Gene transfer vectors."
More… ↓
⤷ Start Trial
|
